Login to Your Account

Biomarker Test Could Accompany Drug

Schizophrenia Bullet? Vanda Submits NDA For Iloperidone

By Randall Osborne

Friday, September 28, 2007
Vanda Pharmaceuticals Inc. followed up its Phase III success late last year with the schizophrenia tablet iloperidone by submitting a new drug application to the FDA. The company is using a personalized-medicine approach, partly to ensure the compound's efficacy and partly to quell any potential safety concerns - namely, problems with prolonged QT intervals, a common bugaboo in the class. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription